<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37487569</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-0962</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Lupus</Title><ISOAbbreviation>Lupus</ISOAbbreviation></Journal><ArticleTitle>Clinical efficacy of centrifugal-membranous hybrid double filtration plasmapheresis and membranous double filtration plasmapheresis on severe lupus nephritis.</ArticleTitle><Pagination><StartPage>1066</StartPage><EndPage>1074</EndPage><MedlinePgn>1066-1074</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/09612033231187229</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The study delves into the clinical efficacy and safety of centrifugal-membranous hybrid double filtration plasmapheresis (C/M hybrid DFPP) on severe lupus nephritis (LN) by comparing it with membranous DFPP (M DFPP).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective cohort study was conducted in 70 patients who were diagnosed with severe LN and had received DFPP treatment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 181 DFPPs were performed, including 133&#xa0;C/M hybrid DFPPs (51 patients) and 48&#xa0;M DFPPs (19 patients).The ANA, A-dsDNA titer, quantitative urinary protein, and serum creatinine decreased significantly and hemoglobin increased significantly after the DFPP treatment and at third month after treatment. Two patients in the M DFPP group developed bleeding complications, and four patients in the C/M hybrid DFPP group developed perioral numbness.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Although there was no significant difference in clinical efficacy between C/M hybrid DFPP and M DFPP on severe LN, the risk of bleeding complications was significantly lower in the C/M hybrid DFPP group.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Jianhua</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7346-1647</Identifier><AffiliationInfo><Affiliation>National Clinical Research Center of kidney Diseases, JinLing Hospital, Nanjing University School of medicine, Nanjing, China.</Affiliation><Identifier Source="RINGGOLD">194042</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>National Clinical Research Center of kidney Diseases, JinLing Hospital, Nanjing University School of medicine, Nanjing, China.</Affiliation><Identifier Source="RINGGOLD">194042</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Chuan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>National Clinical Research Center of kidney Diseases, JinLing Hospital, Nanjing University School of medicine, Nanjing, China.</Affiliation><Identifier Source="RINGGOLD">194042</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Bian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>National Clinical Research Center of kidney Diseases, JinLing Hospital, Nanjing University School of medicine, Nanjing, China.</Affiliation><Identifier Source="RINGGOLD">194042</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>National Clinical Research Center of kidney Diseases, JinLing Hospital, Nanjing University School of medicine, Nanjing, China.</Affiliation><Identifier Source="RINGGOLD">194042</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ge</LastName><ForeName>Yongchun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Clinical Research Center of kidney Diseases, JinLing Hospital, Nanjing University School of medicine, Nanjing, China.</Affiliation><Identifier Source="RINGGOLD">194042</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus</MedlineTA><NlmUniqueID>9204265</NlmUniqueID><ISSNLinking>0961-2033</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010956" MajorTopicYN="N">Plasmapheresis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Double-filtration plasmapheresis</Keyword><Keyword MajorTopicYN="N">adverse events</Keyword><Keyword MajorTopicYN="N">clinical efficacy</Keyword><Keyword MajorTopicYN="N">hybrid</Keyword><Keyword MajorTopicYN="N">severe lupus nephritis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>25</Day><Hour>1</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>24</Day><Hour>19</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37487569</ArticleId><ArticleId IdType="doi">10.1177/09612033231187229</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>